CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.
A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.
Shares of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) were trading at $1.65, down $2.45, or 59%, after the company disclosed phase II results from the Bestow trial testing tegoprubart, which targets ...
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral ...
Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® - Q3 2025 operating profit of €11.0 million - TransCon® CNP (navepegritide) under FDA Priority Review for the ...
Nearly two years ago, Chad Gluss went into cardiac arrest and wound up needing a heart transplant. In January, he will be ...
Beets are a root vegetable that may have benefits for blood pressure management, athletic performance, and more.
According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent ...
Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...
On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
For more than two decades, Bracco has made education a cornerstone of progress in radiology. In 2024 alone, Bracco's educational programs reached over 100,000 healthcare professionals worldwide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback